|
It's a bad line http://www.ajonc.org/katonah-pharmacy-61a6.pdf weinstein katonah pharmacy Roche is seeking approval for Perjeta, which is currently available as a first-line treatment, in combination with Herceptin (trastuzumab) and the chemotherapy docetaxel for neoadjuvant (before surgery) use in patients with HER2-positive early-stage breast cancer. An advisory committee of the FDA, which granted the application a priority review, meets on Thursday (September 12).
|